CytomX, Esperion, Nektar Therapeutics News Today

CytomX Therapeutics Inc, Esperion Therapeutics Inc, and Nektar Therapeutics are in the news today

Mar 20, 2017 at 10:02 AM
facebook X logo linkedin


Stocks are flat in the wake of the G-20 summit, which signaled a potential turn toward protectionism. Among stocks in focus are drugmakers CytomX Therapeutics Inc (NASDAQ:CTMX), Esperion Therapeutics Inc (NASDAQ:ESPR), and Nektar Therapeutics (NASDAQ:NKTR), Here's a quick roundup of the headlines moving shares of CTMX, ESPR, and NKTR -- the top three percentage gainers on the Nasdaq, at last check.

CytomX Stock Sizzles on Bristol-Myers Squibb Deal

CTMX shares are on fire, after the company extended its worldwide collaboration with Bristol-Myers Squibb Co (NYSE:BMY). With CytomX Therapeutics Inc in line to receive $200 million upfront, the stock has soared nearly 30% this morning to $19.71, and hit an annual high of $20.02. While the brokerage crowd has yet to weigh in on the expanded deal with BMY, CTMX has already received plenty of upbeat coverage. Specifically, 75% of analysts rate the stock a "strong buy," without a single "sell" recommendation on the books.

Esperion Explodes on FDA Nod

ESPR announced the U.S. Food and Drug Administration (FDA) has confirmed a regulatory pathway to approval for the drugmaker's heart drug. Not surprisingly, the stock has surged, up 53.3% at $36.28 -- and fresh off an annual high of $37.16 -- recovering from Friday's 20% fall. In fact, Esperion Therapeutics Inc shares have more than doubled in value on a year-over-year basis. One group potentially getting burned today is short sellers. Nearly 32% of ESPR's float is dedicated to these bearish bets, most of which are likely to be underwater following the bull gap.

Successful Study Sets Off Nektar Shares

NKTR is blasting off, as well, gapping up 28.6% to trade at $19.98, and just off a 10-year high of $20.29, after the company's opioid painkiller succeeded in a late-stage study. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have been betting bullishly on the Nektar Therapeutics. The stock's 10-day call/put volume ratio sits at a top-heavy 20.20, ranking just 7 percentage points from an annual high.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI